AACR20: global collaboration provides guidance on how to manage cancer patients with COVID-19

Written by Rachel Jenkins, Future Science Group

Cancer patients with thoracic disease are considered to be at a higher risk of mortality due to SARS-CoV-2 infection, compared with the general population. However, the study results available are limited due to being from single institutions and small sample sizes. In order to overcome these limitations, a global registry called the Thoracic cancERs international coVid 19 cOLlaboraTion (TERAVOLT; a collaboration between 160 institutions across the globe) has been set up with the goal of understanding the relationship between patients with thoracic malignancies and COVID-19, and ultimately guiding oncology professionals on how to manage these patients. Want regular AACR updates...

To view this content, please register now for access

It's completely free